Alan Moses is the associate vice president of medical affairs for Novo Nordisk Inc.
How does Novo Nordisk continue to evolve in the diabetes care industry?
Since we first marketed insulin in 1923, Novo Nordisk has been at the forefront of diabetes research and innovation. Over the years, we have paid particular attention to providing the most purified insulin, and with the advent of recombinant DNA technology, we have focused on developing innovative insulin analogs that can fulfill the needs of the broad spectrum of diabetes patients.
Unlike competitors that focus on several therapeutic disease areas, Novo Nordisk dedicates nearly 75 percent of the company’s resources to diabetes care, affirming that the company is the optimal partner in care to physicians, diabetes educators, patients, third-party organizations, managed care organizations and government.
What is insulin detemir, and what is the most promising thing about it?
Insulin detemir is a new long-acting insulin analog for the treatment of both type 1 and type 2 diabetes. Insulin detemir is a neutral pH soluble basal insulin analog that is characterized by very low variability in serum profiles on a day-to-day basis. In addition, in long-term clinical studies, insulin detemir was associated with some weight loss or minimal weight gain. We believe that insulin detemir will have certain advantages as a basal insulin and that it will improve glucose control for many patients.
What are some other drugs that Novo Nordisk has in the pipeline?
The Novo Nordisk pipeline promises several new products that will continue to exemplify our commitment to treating the full cycle of diabetes and to provide a solution to every patient with diabetes. Further down the road is the AERx Insulin Diabetes Management System (iDMS), an inhaled insulin being developed for type 1 and type 2 diabetes. Last year, Novo Nordisk acquired full development and manufacturing rights to AERx iDMS.
Another exciting product in the pipeline is liraglutide, an investigational therapy for type 2 diabetes based on the naturally occurring hormone glucagon-like peptide-1 (GLP-1). GLP-1 and inhaled insulin are the latest breakthrough technologies and newest classes of drugs in diabetes care, with the potential to substantially change the approach to diabetes treatment.
What educational materials do Novo Nordisk offer the healthcare professional?
Novo Nordisk provides grants for continuing education programs and materials on topics related to diabetes management and the appropriate use of insulin and delivery devices. These programs and materials are available to the many varied healthcare professionals involved in diabetes care, including physicians, pharmacists, nurses, dietitians, case managers and nurse practitioners. In addition, physicians can visit www.NovoMedLink.com to participate in interactive learning programs focused on therapeutic options around treating diabetes and insulin and delivery devices.
What is the future of insulin, and how will Novo Nordisk continue to be an industry leader?
While Novo Nordisk and other companies will introduce exciting new diabetes therapies in the next few years, we expect insulin to remain an important part of effective diabetes therapy. Unfortunately, we have learned from the natural history of type 2 diabetes that insulin secretion continues to decline over time, and that eventually insulin therapy is required in a large number of patients to achieve acceptable glucose control. With the continuing increase in the prevalence of diabetes and its younger age of onset, insulin therapy will continue to be the mainstay of diabetes control for an increasing number of patients.Click Here To View Or Post Comments